PedAM
Pediatric Disease Annotations & Medicines
| pyelonephritis | ||||
| Disease ID | 1119 |
|---|---|
| Disease | pyelonephritis |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:13) C0009450 | infection | 10 C0036690 | sepsis | 7 C0004659 | bacteriuria | 5 C0035078 | renal failure | 5 C1565489 | renal insufficiency | 2 C0022660 | acute renal failure | 2 C0004623 | bacterial infection | 1 C0040053 | thrombosis | 1 C0022661 | end-stage renal failure | 1 C0022876 | preterm labor | 1 C0020538 | hypertension | 1 C0002871 | anemia | 1 C0403447 | chronic renal insufficiency | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:11) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0034186 | carbenicillin | D002228 | 4697-36-3 | pyelonephritis | MESH:D011704 | therapeutic | 5171074 | ||
| C0034186 | cefotaxime | D002439 | 63527-52-6 | pyelonephritis | MESH:D011704 | therapeutic | 2943665 | ||
| C0034186 | ciprofloxacin | D002939 | 85721-33-1 | pyelonephritis | MESH:D011704 | therapeutic | 21410941 | ||
| C0034186 | cyclophosphamide | D003520 | 50-18-0 | pyelonephritis | MESH:D011704 | marker/mechanism | 1488776 | ||
| C0034186 | daptomycin | D017576 | 103060-53-3 | pyelonephritis | MESH:D011704 | therapeutic | 18349306 | ||
| C0034186 | disopyramide | D004206 | 3737/9/5 | pyelonephritis | MESH:D011704 | marker/mechanism | 6486998 | ||
| C0034186 | fenoprofen | D005279 | 31879-05-7 | pyelonephritis | MESH:D011704 | marker/mechanism | 486229 | ||
| C0034186 | indomethacin | D007213 | 53-86-1 | pyelonephritis | MESH:D011704 | therapeutic | 448822 | ||
| C0034186 | loracarbef | C054920 | - | pyelonephritis | MESH:D011704 | therapeutic | 1621752 | ||
| C0034186 | ofloxacin | D015242 | 82419-36-1 | pyelonephritis | MESH:D011704 | therapeutic | 8913458 | ||
| C0034186 | piperacillin | D010878 | 61477-96-1 | pyelonephritis | MESH:D011704 | therapeutic | 3945861 | ||
FDA approved drug and dosage information(Total Drugs:2) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D011704 | cipro | ciprofloxacin | 400MG/40ML (10MG/ML) | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
| MESH:D011704 | cipro | ciprofloxacin | 250MG/5ML | FOR SUSPENSION;ORAL | Prescription | AB | Yes | No |
FDA labeling changes(Total Drugs:2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D011704 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |
| MESH:D011704 | 03/25/2004 | cipro | ciprofloxacin | Complicated UTI and pyelonephritis | Indicated for the treatment of complicated urinary tract infections (cUTIs) and pyelonephritis in pediatric patients 1 17 years of age Not drug of first choice due to increased adverse events compared to controls including events related to joints and/or surrounding tissues Information on PK and dose in pediatric patients 1 17 years of age The most frequent adverse events observed within 6 weeks of treatment initiation during the cUTI clinical trial were gastrointestinal 15% compared to 9% and musculoskeletal 9.3% compared to 6% in ciprofloxacin-treated compared to control-treated patients, respectively | Labeling | B | - | - | - | Bayer | 12/18/2003 | FALSE' |